Previous Article | Next Article ![]()
Infection and Immunity, August 2001, p. 5177-5181, Vol. 69, No. 8
Department of Molecular Microbiology and
Immunology, University of Missouri School of Medicine, Columbia,
Missouri 65212
Received 20 March 2001/Accepted 25 May 2001
A new mechanism expanding mycoplasmal surface diversity is
described. Exposure of surface epitopes on a constitutively expressed membrane protein (P56) of Mycoplasma hominis was subject to
high-frequency phase variation due to phase-variable expression of the
P120 antigen and its selective masking of P56 epitopes. Phase-variable
masking may confer previously unrealized adaptive capabilities on mycoplasmas.
Many species of mycoplasma are causative agents of
infectious diseases in plants and animals, including humans. Due to the lack of cell walls and surface appendages common to other eubacteria, the membrane proteins of many mycoplasmas are directly involved in
mycoplasma-host interaction and play crucial roles in mycoplasma pathogenesis (14, 21). A common strategy utilized by
pathogenic mycoplasmas for adaptation in a host appears to be the rapid
diversification of surface protein expression and structure (22,
26), as recently reviewed in reference 14. Such
changes lead to a dynamic phenotypic variation that may contribute to
successful infection. Differential expression of mycoplasma surface
proteins, which to date has been found to occur by promoter mutation
(5, 27), DNA inversion (1, 17), or frameshift
mutation (20, 29), has been widely implicated in
phenotypic variation of mycoplasma populations. In addition, it has
been indirectly suggested that variable expression of particular
surface proteins may affect other membrane molecules (4, 16,
19).
We have used Mycoplasma hominis, a human pathogen associated
with clinically diverse diseases (including urogenital infections, postpartum fever, and arthritis) (8), as a model system
with which to study adaptive mechanisms of pathogenic mycoplasmas in the human host. Several surface lipoproteins of M. hominis,
including the Vaa adhesin, P120, and Lmp, have been characterized in
previous studies by us and others. Vaa is subject to size, phase, and
antigenic variations in clonal populations and among strains of
M. hominis (2, 6, 28, 29). We have shown in
clinical isolate 1620 of M. hominis that (i) size variation
of Vaa is caused by gain or loss of the tandem repetitive sequences in
the central region of this protein; (ii) C-terminal sequence divergence
of Vaa leads to antigenic variation among strains, as shown also by
others in diverse isolates (2, 6); and (iii)
single-nucleotide insertions or deletions in a polyadenine tract within
the 5' end of the vaa coding region create reversible
frameshift mutations causing variable expression of Vaa, with
concurrent alterations of M. hominis adherence to human
cells in vitro (29). The abundant P120 surface lipoprotein
contains a hypervariable N-terminal region, two central semivariable
domains, and a highly conserved C-terminal region (3, 12).
The hypervariable domain of P120 is exposed on the mycoplasma surface
and is the target of a strong humoral response in the human host, while
the conserved C-terminal region is not. The role of P120 has not been
determined. Lmp antigens, encoded by a multiple-gene family, are also
surface exposed and size variable among strains (9, 10).
Lmp antigens contain multiple internal repeats, with primary sequences
that are highly conserved among Lmp members. Deletion of repeats in Lmp
antigens causes aggregation of mycoplasmas in broth culture, suggesting that this protein too may contribute to the surface properties of
M. hominis (7).
In this report, we define a previously unknown, abundant surface
protein (designated P56) in M. hominis isolate 1630 and
provide direct evidence that phase-variable expression of the P120
lipoprotein affects the surface display of epitopes on the P56 protein,
despite constitutive expression of P56 in this isolate. Specifically, (i) P56 exposure on the mycoplasma surface is subject to phase variation, as detected by colony immunoblotting with antibody (Ab) to
this protein; (ii) the P56 product was constantly expressed in clonal
lineages of isolate 1630, despite its variable surface exposure to Ab;
and (iii) high-frequency phase variation in the expression of P120
appears directly and specifically to mask or unmask P56 epitopes, but
not those of other surface antigens, thereby leading to selective phase
variation in the surface phenotype of P56.
M. hominis isolates 1620 and 1630 were provided by Lyn D. Olson and Michael Barile, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Md. These two isolates were
recovered successively from a knee joint of a single patient who
developed M. hominis-associated arthritis (13,
18). These isolates and M. hominis type strain PG21
(28) were propagated in our laboratory for two to three
passages in modified Hayflick medium (25) supplemented
with 20% heat-inactivated horse serum and 0.25% arginine. Clonal
lineages of isolate 1630 were derived as previously described
(15). Monoclonal Ab (MAb) 26.7D, which is specific for the
hypervariable region of the P120 lipoprotein of M. hominis
(3), was provided by Gunna Christiansen, University of
Aarhus, Aarhus, Denmark. Extraction of M. hominis membrane proteins with Triton X-114 (TX-114) was performed as described elsewhere (24). Sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (SDS-PAGE) (11), Western immunoblotting,
and colony immunoblotting (using mycoplasma colonies grown for 2 to 3 days on agar plates) were performed as described previously (28,
29).
P56 is a novel protein expressed in isolate 1630.
In the
process of characterizing variable proteins in successive M. hominis isolates 1620 and 1630, we observed that isolate 1630 expressed a previously unobserved, abundant membrane protein with a
molecular mass of 56 kDa that partitioned in the TX-114 phase (Fig.
1A). This protein was designated P56 and was shown to be
metabolically labeled by [35S]cysteine (data not shown),
consistent with the characteristics of mycoplasma lipoproteins
(24). P56 appeared to be absent from isolate 1620 and the
type strain PG21 as measured by these methods. This apparent strain
difference in P56 could arise from its inability to be expressed or
from a negative state of phase variation in the 1620 population
propagated (although there is no evidence supporting the latter
possibility). Assorted MAbs recognizing different M. hominis
surface antigens (28) did not react with the P56 protein
(Fig. 1B and data not shown). To generate specific Ab to P56,
TX-114-fractionated membrane proteins of isolate 1630 were separated by
SDS-PAGE and bands were visualized by negative staining with sodium
acetate (23). The P56 band, well isolated from other
proteins, was excised from the gel and electroeluted (S&S Elutrap;
Schleicher & Schuell). Analysis of the eluate by SDS-PAGE revealed only
the single 56-kDa protein (data not shown). The eluted protein was
emulsified with incomplete Freund adjuvant and used to inoculate BALB/c
mice as described previously (23). Western immunoblotting
of membrane proteins from isolates 1620 and 1630 with preimmune or
hyperimmune mouse serum demonstrated that the antiserum was highly
specific for the P56 protein of isolate 1630 (Fig. 1C). The Ab to P56
failed to detect any proteins in isolate 1620 or in strain PG21. This
suggested that P56 is not antigenically related to Vaa or other
membrane proteins of M. hominis and that it may be
restricted in its strain distribution.
0019-9567/01/$04.00+0 DOI: 10.1128/IAI.69.8.5177-5181.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Coupled Phase-Variable Expression and Epitope Masking of
Selective Surface Lipoproteins Increase Surface Phenotypic
Diversity in Mycoplasma hominis
and
![]()
ABSTRACT
Top
Abstract
Text
References
![]()
TEXT
Top
Abstract
Text
References

View larger version (47K):
[in a new window]
FIG. 1.
SDS-PAGE and immunoblotting analysis of
TX-114-partitioned membrane proteins of M. hominis isolates
1620 (lane 1) and 1630 (lane 2). Panel A shows a gel stained with
Coomassie brilliant blue. Panels B and C show Western blots of the same
samples immunostained, respectively, with MAb H3 (28),
which is specific for a conserved epitope on Vaa (B), or specific
polyclonal antiserum to P56 (C). Protein molecular size markers are
indicated at the left of panel A. The position of P56 is indicated by
the arrows.
P56 is expressed on the surface of M. hominis and
undergoes phase variation in surface display.
To determine whether
P56 is exposed on the surface of M. hominis, mycoplasma
colony lifts (24) from a clonal isolate (CL3.8) of isolate
1630 were immunostained with Ab to P56. Surprisingly, colonies of this
clonal population were not uniformly stained with the Ab (Fig.
2A). Most colonies of CL3.8 were only weakly stained
with Ab to P56 and were subsequently designated P56
in
this study. In contrast, a minority of the colonies were strongly stained (designated P56+) or showed sectored staining
patterns. To further examine variation of this surface phenotype, a
single P56+ colony was selected from the P56
population, replated on mycoplasma agar plates, and immunoblotted with
Ab to P56 (Fig. 2B). In this case, the majority of the colonies were
P56+; however, a few were P56
or showed a
sectored staining pattern. Isolation and replating of variants
oscillating in their staining patterns with Ab to P56 established
lineages that defined phase variation of P56 in clonal populations of
M. hominis. These results indicated that P56 is localized on
the surface of mycoplasma and that its surface display (measured by
specific Ab binding) is subject to variation in clonal populations.
This phase variation occurred at a frequency of approximately
10
2.
|
Phase variation of P56 surface epitope display is not related to differential expression of this protein. To determine the molecular basis of P56 phenotypic variation detected by colony immunoblotting, membrane proteins from successive clonal variants in a lineage of isolate 1630 oscillating in the staining patterns with Ab to P56 were analyzed by SDS-PAGE and Western blotting. After staining with Coomassie brilliant blue, the P56 band in each variant was quantified digitally with an IS-1000 digital imaging system (Alpha Innotech Corporation) using the G5 antigen (29) and a 100-kDa membrane protein (P100) as invariant internal standards in this lineage. As shown in Fig. 2C, the P56 product was constantly expressed, with similar relative abundance in each variant, despite marked switching in the surface display of epitopes recognized by cognate Ab (Fig. 2A and B). Western immunoblotting of these switching variants with Ab to P56 confirmed this observation (Fig. 2D). These findings demonstrated that phase variation of P56 is associated with the altered exposure of P56 surface epitopes rather than variable expression of the protein. This raised the possibility that P56 interacts in some way with another phase-variable component on the mycoplasma surface.
Variable expression of P120 selectively affects the surface display
of P56.
To determine if phase variation of P56 is related to the
expression profiles of other membrane proteins, successive clonal variants oscillating in P56 surface display were further examined by
SDS-PAGE and Western blotting. This revealed a striking inverse correlation between the expression of a 120-kDa protein and the variable P56 phenotype. The 120-kDa protein was produced only in
P56
variants and not in P56+ variants (Fig.
2C). Moreover, expression of other membrane proteins in these variants
did not change. These observations provided a strong rationale for
further examining the relationship between variable expression of the
120-kDa protein and the surface display of P56.
variants but did not
detect any protein bands in P56+ variants (Fig. 2E),
confirming that the phase-variable protein is, indeed, the P120
identified previously. Three lineages of clonal variants oscillating in
patterns of staining with Ab to P56 were independently derived from
isolate 1630. In each lineage, the expression status of P120 was always
inversely correlated with the surface display of P56 epitopes. One
lineage is depicted in Fig. 2C to E. To further examine the precise,
inverse relationship between the phenotypes, colony blots of
P56
or P56+ variants were immunostained with
MAb 26.7D, showing the striking variation of P120 in clonal populations
(Fig. 3A and B). In these clonal lineages and in
otherwise unselected populations of M. hominis, a switching
frequency of 10
2 was observed for P120 expression. As
expected, most of the colonies in the P56+ population were
only weakly stained with MAb 26.7D, whereas the majority of the
colonies in the P56
population were strongly stained with
this MAb. Furthermore, sectored colonies were observed in both
populations. Immunostaining of replicate colony blots with MAb 26.7D or
the anti-P56 Ab demonstrated a consistent, reciprocal staining pattern,
even on sectored colonies (Fig. 3C and D). Together, these results
establish that (i) P120 undergoes high-frequency phase variation by
differential expression in clonal populations and (ii) on-off switching
in the expression of P120 precisely correlates with changes in the
surface accessibility of P56 epitopes, despite continuous expression of
the P56 product. These results strongly suggest that phase variation
governing the surface display of P56 in isolate 1630 results from a
mechanism involving masking by the P120 lipoprotein. Masking of P56 by
P120 appeared to be selective for P56 because the expression of P120 did not affect the surface exposure of other known membrane proteins, including the invariant G5 protein (data not shown) or the Vaa adhesin,
previously shown in strain 1620 to phase vary independently of P120
expression (29). Vaa is not expressed in the 1630 lineages examined in the current study.
|
colonies were still weakly stained by the anti-P56
Ab. In contrast, mycoplasma colonies of strain 1620, which does not
express P56, did not react at all with the anti-P56 Ab in the colony
immunoblotting assay. Two possibilities might explain the partial
nature of masking: (i) only part of the P56 protein is masked by P120,
leaving specific epitopes accessible to selected Ab populations in the
polyclonal antiserum to P56, or (ii) only a portion of the P56 proteins
present on the surface is masked by P120. The relative abundance of
P120 and P56 remains to be formally determined.
P120 is encoded by a single-copy p120 gene on the M. hominis chromosome (3). Comparison of p120
alleles in different strains has revealed that P120 contains a
hypervariable N-terminal region and a highly conserved C-terminal
region (12). The hypervariable region of P120 is exposed
on the mycoplasma surface and is immunodominant in the human host,
while the highly conserved C-terminal region of P120 is apparently not
a target of the humoral immune response. Variable expression among
M. hominis strains and antigenic variation related to the
hypervariable region of P120 have been documented (12).
However, high-frequency phase variation, requiring analysis of
reversible switching in clonal populations, has not been previously demonstrated. Clonal variants oscillating in the expression of the P120
product described in this study formally define high-frequency phase
variation in the expression of the P120 product in clonal populations.
The genetic basis for differential expression of P120 in clonal
variants remains to be determined. Interestingly, a long, homopolymeric
tract of thymidine residues flanking the 5' end of the p120
gene has been reported (3). Whether this is subject to
mutations affecting transcription is not known.
Isolates 1620 and 1630 were obtained successively from the knee joint
of a single patient (13, 18). The occurrence of P56 in
isolate 1630 is interesting in light of its apparent absence from
other strains. Whether this is a fortuitous manifestation of
phase variation or reflects some other event in the propagating population in this host niche remains to be determined.
Nevertheless, the findings we report here define a complex system
generating surface diversity in a human mycoplasma pathogen. Interplay
of multiple mechanisms (differential expression and surface masking) affecting the variation of surface proteins may confer great
flexibility on mycoplasmas in adapting to host niches.
| |
ACKNOWLEDGMENTS |
|---|
We thank Gunna Christiansen for providing MAbs and Lyn Olson and Michael Barile for providing M. hominis isolates.
This study was supported in part by DHHS grants AR42537 (K.S.W.) from the National Institute of Arthritis and Musculoskeletal and Skin Diseases and AI32219 (K.S.W.) and T32 AI07276 (Q.Z.) from the National Institute of Allergy and Infectious Diseases.
| |
FOOTNOTES |
|---|
* Corresponding author. Mailing address: Department of Molecular Microbiology and Immunology, University of Missouri School of Medicine, Columbia, MO 65212. Phone: (573) 882-8988. Fax: (573) 882-4287. E-mail: wisek{at}missouri.edu.
Present address: Food Animal Health Research Program, Department of
Veterinary Preventive Medicine, The Ohio State University, Wooster, OH 44691.
Editor: R. N. Moore
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Bhugra, B., L. R. Voelker, N. Zou, H. Yu, and K. Dybvig. 1996. Mechanism of antigenic variation in Mycoplasma pulmonis: interwoven, site-specific DNA inversions. Mol. Microbiol. 18:703-714. |
| 2. | Boesen, T., J. Emmersen, L. T. Jensen, S. A. Ladefoged, P. Thorsen, S. Birkelund, and G. Christiansen. 1998. The Mycoplasma hominis vaa gene displays a mosiac gene structure. Mol. Microbiol. 1:97-110. |
| 3. | Christiansen, G., S. L. Mathiesen, C. Nyvold, and S. Birkelund. 1994. Analysis of a Mycoplasma hominis membrane protein, P120. FEMS Microbiol. Lett. 121:121-128[CrossRef][Medline]. |
| 4. | Citti, C., M. F. Kim, and K. S. Wise. 1997. Elongated versions of Vlp surface lipoproteins protect Mycoplasma hyorhinis escape variants from growth-inhibiting host antibodies. Infect. Immun. 65:1773-1785[Abstract]. |
| 5. | Citti, C., and K. S. Wise. 1995. Mycoplasma hyorhinis vlp gene transcription: critical role in phase variation and expression of surface lipoproteins. Mol. Microbiol. 18:649-660[CrossRef][Medline]. |
| 6. | Henrich, B., A. Kitzerow, R. C. Feldmann, H. Schaal, and U. Hadding. 1996. Repetitive elements of the Mycoplasma hominis adhesin p50 can be differentiated by monoclonal antibodies. Infect. Immun. 64:4027-4034[Abstract]. |
| 7. | Jensen, L. T., S. Ladefoged, S. Birkelund, and G. Christiansen. 1995. Selection of Mycoplasma hominis PG21 deletion mutants by cultivation in the presence of monoclonal antibody 552. Infect. Immun. 63:3336-3347[Abstract]. |
| 8. | Krause, D. C., and D. Taylor-Robinson. 1992. Mycoplasmas which infect humans, p. 417-444. In J. Maniloff, R. N. McElhaney, L. R. Finch, and J. B. Baseman (ed.), Mycoplasmas: molecular biology and pathogenesis. American Society for Microbiology, Washington, D.C. |
| 9. | Ladefoged, S. A., S. Birkelund, S. Hauge, B. Brock, L. T. Jensen, and G. Christiansen. 1995. A 135-kilodalton surface antigen of Mycoplasma hominis PG21 contains multiple directly repeated sequences. Infect. Immun. 63:212-223[Abstract]. |
| 10. |
Ladefoged, S. A.,
L. T. Jensen,
B. Brock,
S. Birkelund, and G. Christiansen.
1996.
Analysis of 0.5-kilobase-pair repeats in the Mycoplasma hominis lmp gene system and identification of gene products.
J. Bacteriol.
178:2775-2784 |
| 11. | Laemmli, U. K. 1970. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227:680-685[CrossRef][Medline]. |
| 12. | Nyvold, C., S. Birkelund, and G. Christiansen. 1997. The Mycoplasma hominis P120 membrane protein contains a 216 amino acid hypervariable domain that is recognized by the human humoral immune response. Microbiology 143:675-688[Abstract]. |
| 13. |
Olson, L. D.,
S. W. Shane,
A. A. Karpas,
T. M. Cunningham,
P. S. Probst, and M. F. Barile.
1991.
Monoclonal antibodies to surface antigens of a pathogenic Mycoplasma hominis strain.
Infect. Immun.
59:1683-1689 |
| 14. |
Razin, S.,
D. Yogev, and Y. Naot.
1998.
Molecular biology and pathogenicity of mycoplasmas.
Microbiol. Mol. Biol. Rev.
62:1094-1156 |
| 15. |
Rosengarten, R., and K. S. Wise.
1990.
Phenotypic switching in mycoplasmas: phase variation of diverse surface lipoproteins.
Science
247:315-318 |
| 16. | Rosengarten, R., and D. Yogev. 1996. Variant colony surface antigenic phenotypes within mycoplasma strain populations: implications for species identification and strain standardization. J. Clin. Microbiol. 34:149-158[Abstract]. |
| 17. | Simmons, W. L., C. Zuhua, J. I. Glass, J. W. Simecka, G. H. Cassell, and H. L. Watson. 1996. Sequence analysis of the chromosomal region around and within the V-1-encoding gene of Mycoplasma pulmonis: evidence for DNA inversion as a mechanism for V-1 variation. Infect. Immun. 64:472-479[Abstract]. |
| 18. | Sneller, M., F. Wellborne, M. F. Barile, and P. Plotz. 1986. Prosthetic joint infection with Mycoplasma hominis. J. Infect. Dis. 153:174-175[Medline]. |
| 19. | Theiss, P., A. Karpas, and K. S. Wise. 1996. Antigenic topology of the P29 surface lipoprotein of Mycoplasma fermentans: differential display of epitopes results in high-frequency phase variation. Infect. Immun. 64:1800-1809[Abstract]. |
| 20. |
Theiss, P., and K. S. Wise.
1997.
Localized frameshift mutation generates selective, high-frequency phase variation in a surface lipoprotein encoded by a mycoplasma ABC transporter operon.
J. Bacteriol.
179:4013-4022 |
| 21. | Tryon, V. V., and J. B. Baseman. 1992. Pathogenic determinants and mechanisms, p. 457-471. In J. Maniloff, R. N. McElhaney, L. R. Finch, and J. B. Baseman (ed.), Mycoplasmas: molecular biology and pathogenesis. American Society for Microbiology, Washington, D.C. |
| 22. | Wise, K. S. 1993. Adaptive surface variation in mycoplasmas. Trends Microbiol. 1:59-63[CrossRef][Medline]. |
| 23. |
Wise, K. S., and M. F. Kim.
1987.
Major membrane surface proteins of Mycoplasma hyopneumoniae selectively modified by covalently bound lipid.
J. Bacteriol.
169:5546-5555 |
| 24. | Wise, K. S., M. F. Kim, and R. Watson-McKown. 1995. Variant membrane proteins, p. 227-241. In S. Razin, and J. G. Tully (ed.), Molecular and diagnostic procedures in mycoplasmology. Academic Press, Inc., New York, N.Y. |
| 25. |
Wise, K. S., and R. K. Watson.
1983.
Mycoplasma hyorhinis GDL surface protein antigen p120 defined by monoclonal antibody.
Infect. Immun.
41:1332-1339 |
| 26. | Wise, K. S., D. Yogev, and R. Rosengarten. 1992. Antigenic variation, p. 473-490. In J. Maniloff, R. N. McElhaney, L. R. Finch, and J. B. Baseman (ed.), Mycoplasmas: molecular biology and pathogenesis. American Society for Microbiology, Washington, D.C. |
| 27. | Yogev, D., R. Rosengarten, R. Watson-McKown, and K. S. Wise. 1991. Molecular basis of Mycoplasma surface antigenic variation: a novel set of divergent genes undergo spontaneous mutation of periodic coding regions and 5' regulatory sequences. EMBO J. 10:4069-4079[Medline]. |
| 28. | Zhang, Q., and K. S. Wise. 1996. Molecular basis of size and antigenic variation of a Mycoplasma hominis adhesin encoded by divergent vaa genes. Infect. Immun. 64:2737-2744[Abstract]. |
| 29. | Zhang, Q., and K. S. Wise. 1997. Localized reversible frameshift mutation in an adhesin gene confers a phase-variable adherence phenotype in mycoplasma. Mol. Microbiol. 25:859-869[CrossRef][Medline]. |
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| J. Bacteriol. | J. Virol. | Eukaryot. Cell |
|---|
| Microbiol. Mol. Biol. Rev. | Clin. Vaccine Immunol. | All ASM Journals |
|---|